Particle.news
Download on the App Store
3 ARTICLES
·
last wk.

Oxford Launches £118 Million AI Vaccine Programme With Ellison Institute

Oxford will pair human challenge studies with Ellison Institute AI to speed vaccine design against drug-resistant bacteria.

image: ©Thiago Santos| iStock
The CoI-AI programme will examine the immune system's response to pathogens causing severe infections and antibiotic resistance. Credit: Anggalih Prasetya/Shutterstock.com.
Image

Overview

  • The CoI-AI initiative aims to pinpoint immune correlates of protection by combining controlled human exposure studies with high-resolution immunology and computational analysis.
  • Initial research will focus on Streptococcus pneumoniae, Staphylococcus aureus and E. coli, which are major sources of severe infection and antibiotic resistance.
  • The Oxford Vaccine Group is leading the programme under Professor Sir Andrew Pollard, leveraging its experience from running COVID-19 vaccine trials.
  • The Ellison Institute will provide advanced AI expertise and Oracle-enabled computing power, complemented by a scholars programme to develop research talent.
  • The launch builds on a 2024 Oxford–EIT strategic alliance, and trial designs and regulatory approvals are being prepared with specific timelines yet to be announced.